Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

IL-2 stimulant

DRUG CLASS:

IL-2 stimulant

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	aldesleukin Sensitive: A1 - Approval aldesleukin Sensitive : A1	aldesleukin Sensitive: A1 - Approval aldesleukin Sensitive : A1
IL2RA expression	Cutaneous T-cell Lymphoma	IL2RA expression	Cutaneous T-cell Lymphoma	denileukin diftitox Sensitive: A1 - Approval denileukin diftitox Sensitive : A1	denileukin diftitox Sensitive: A1 - Approval denileukin diftitox Sensitive : A1
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	denileukin diftitox Sensitive: A1 - Approval denileukin diftitox Sensitive : A1	denileukin diftitox Sensitive: A1 - Approval denileukin diftitox Sensitive : A1
No biomarker	Cutaneous T-cell Lymphoma	No biomarker	Cutaneous T-cell Lymphoma	denileukin diftitox Sensitive: A1 - Approval denileukin diftitox Sensitive : A1	denileukin diftitox Sensitive: A1 - Approval denileukin diftitox Sensitive : A1
No biomarker	Melanoma	No biomarker	Melanoma	aldesleukin Sensitive: A1 - Approval aldesleukin Sensitive : A1	aldesleukin Sensitive: A1 - Approval aldesleukin Sensitive : A1
No biomarker	Cutaneous T-cell Lymphoma	No biomarker	Cutaneous T-cell Lymphoma	denileukin diftitox-cxdl Sensitive: A1 - Approval denileukin diftitox-cxdl Sensitive : A1	denileukin diftitox-cxdl Sensitive: A1 - Approval denileukin diftitox-cxdl Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	CUE-101 Sensitive: B - Late Trials CUE-101 Sensitive : B	CUE-101 Sensitive: B - Late Trials CUE-101 Sensitive : B
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	AVB-001 Sensitive: B - Late Trials AVB-001 Sensitive : B	AVB-001 Sensitive: B - Late Trials AVB-001 Sensitive : B
IL2RA expression	Peripheral T-cell Lymphoma	IL2RA expression	Peripheral T-cell Lymphoma	denileukin diftitox Sensitive: C1 - Off-label denileukin diftitox Sensitive : C1	denileukin diftitox Sensitive: C1 - Off-label denileukin diftitox Sensitive : C1
PD-1 expression	Sarcoma	PD-1 expression	Sarcoma	nivolumab + NKTR-214 Sensitive: C3 – Early Trials nivolumab + NKTR-214 Sensitive : C3	nivolumab + NKTR-214 Sensitive: C3 – Early Trials nivolumab + NKTR-214 Sensitive : C3
HLA-A*02:01 + PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	HLA-A*02:01 + PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab + CUE-101 Sensitive: C3 – Early Trials pembrolizumab + CUE-101 Sensitive : C3	pembrolizumab + CUE-101 Sensitive: C3 – Early Trials pembrolizumab + CUE-101 Sensitive : C3
HLA-A*02:01	Squamous Cell Carcinoma of Head and Neck	HLA-A*02:01	Squamous Cell Carcinoma of Head and Neck	CUE-101 Sensitive: C3 – Early Trials CUE-101 Sensitive : C3	CUE-101 Sensitive: C3 – Early Trials CUE-101 Sensitive : C3
CD8 positive	Fibrosarcoma	CD8 positive	Fibrosarcoma	NKTR-214 Sensitive: D – Preclinical NKTR-214 Sensitive : D	NKTR-214 Sensitive: D – Preclinical NKTR-214 Sensitive : D
CD8 positive	Colorectal Cancer	CD8 positive	Colorectal Cancer	NKTR-214 Sensitive: D – Preclinical NKTR-214 Sensitive : D	NKTR-214 Sensitive: D – Preclinical NKTR-214 Sensitive : D